Know What's Happening in BioTech

Protein‐Capturing Microgel‐Integrated Microneedle Array Patches for Enhanced Tip‐Loading, Storage Stability, and Transdermal Delivery of Recombinant Proteins
NewsJan 23, 2026

Protein‐Capturing Microgel‐Integrated Microneedle Array Patches for Enhanced Tip‐Loading, Storage Stability, and Transdermal Delivery of Recombinant Proteins

Researchers introduced a microgel‑integrated microneedle array patch (MI‑MAP) that concentrates recombinant proteins at the needle tips and stabilizes them through phenolic interactions. Compared with conventional hydrogel‑based patches, MI‑MAP achieved markedly higher tip‑loading efficiency and maintained protein activity after 28 days at...

By Small (Wiley)
Breath-Based Testing Emerges as Tool for Monitoring Microbiome Health
NewsJan 23, 2026

Breath-Based Testing Emerges as Tool for Monitoring Microbiome Health

Researchers at Washington University School of Medicine and the Children’s Hospital of Philadelphia demonstrated that volatile organic compounds (VOCs) in exhaled breath accurately reflect gut microbiome composition in children and gnotobiotic mice. By correlating breath VOC profiles with stool metagenomics,...

By GEN (Genetic Engineering & Biotechnology News)
Mild Photothermal Stimulation Driven Nanoparticles Hybrid Dual‐Network Hydrogels for Bone Repair
NewsJan 23, 2026

Mild Photothermal Stimulation Driven Nanoparticles Hybrid Dual‐Network Hydrogels for Bone Repair

The researchers present a PDA@GelMA/HA-DA/Fe3+ dual‑network hydrogel that combines gelatin methacryloyl, dopamine‑modified hyaluronic acid, Fe3+ crosslinking and polydopamine nanoparticles. Fe3+ ions act as angiogenic cues while the nanoparticles provide mild photothermal stimulation under near‑infrared light. In vitro, bone‑marrow mesenchymal stem...

By Small (Wiley)
AI-Designed Drugs Double Phase‑I Success Rate
SocialJan 23, 2026

AI-Designed Drugs Double Phase‑I Success Rate

Phase I AI-discovered molecules show an 80-90% success rate in Ph1-to-Ph2 transition. *vs historic benchmark ~50% https://t.co/rC03gNjOPo https://t.co/AcK2XxfrW0

By BowTiedBiotech
Reduced Mechanical Stimulation in Aged Bone Marrow Contributes to Cell Dysfunction
BlogJan 23, 2026

Reduced Mechanical Stimulation in Aged Bone Marrow Contributes to Cell Dysfunction

Researchers discovered that aging diminishes mechanical stimulation in bone marrow, lowering intracellular traction forces of mesenchymal stem cells. Applying low‑frequency vibration restores these forces, re‑opening chromatin and reactivating FOXO1 transcription. The mechanical rescue improves locomotor activity, reduces frailty, and dampens...

By Fight Aging!
TNFα Contributes to Age-Related Liver and Intestinal Barrier Dysfunction
BlogJan 23, 2026

TNFα Contributes to Age-Related Liver and Intestinal Barrier Dysfunction

Chronic, age‑related inflammation elevates hepatic TNFα and senescence markers p16 and p21 in male C57BL/6J mice. When TNFα is genetically deleted, 24‑month‑old mice show markedly reduced liver inflammation, fibrosis, and cellular senescence compared with wild‑type controls. The knockout also preserves...

By Fight Aging!
Uncovering Two Key Enzymes in Tilianin Biosynthesis
NewsJan 23, 2026

Uncovering Two Key Enzymes in Tilianin Biosynthesis

Researchers have pinpointed two enzymes—flavonoid 3'-hydroxylase and a specific glycosyltransferase—that drive the final steps of tilianin biosynthesis in medicinal plants. The findings, published in a peer‑reviewed journal, map the enzymatic cascade and confirm the pathway’s regulatory nodes. By transferring these...

By Bioengineer.org
Ferroptosis in Cancer: Metabolism and Therapeutic Opportunities
NewsJan 23, 2026

Ferroptosis in Cancer: Metabolism and Therapeutic Opportunities

Ferroptosis, an iron‑dependent form of regulated cell death, is gaining traction as a novel anticancer target. Recent research highlights how tumor metabolism—particularly iron overload and lipid peroxidation—creates vulnerabilities that can be exploited therapeutically. Agents that disrupt glutathione synthesis or block...

By Bioengineer.org
Breast Cancer’s Metabolic Weaknesses From Isozyme Loss
NewsJan 23, 2026

Breast Cancer’s Metabolic Weaknesses From Isozyme Loss

A recent study reveals that loss of specific metabolic isozymes creates exploitable weaknesses in breast cancer cells. Researchers identified that isozyme depletion disrupts glycolysis and oxidative phosphorylation, rendering tumors dependent on alternative pathways. Pre‑clinical models showed that targeting these compensatory...

By Bioengineer.org
Top 5 Trends that Will Drive Biopharma in the Next Decade with Tim Opler
NewsJan 23, 2026

Top 5 Trends that Will Drive Biopharma in the Next Decade with Tim Opler

Tim Opler, Managing Director at Stifel’s Global Healthcare Group, released his December 2025 Biopharma Market Update outlining five macro‑trends that will shape the industry over the next ten years. He highlights an accelerating M&A wave, the emergence of multi‑trillion‑dollar therapeutic markets...

By Labiotech.eu
Mendra Raises $82M in Series A Funding
NewsJan 23, 2026

Mendra Raises $82M in Series A Funding

Mendra, a San Francisco‑based biopharma focused on rare‑disease therapies, announced an $82 million Series A round. The financing was co‑led by OrbiMed, 8VC and 5AM Ventures, with Lux Capital and Wing VC also participating. The capital will fund the acquisition and development of...

By FinSMEs
Integrating Smartphone Apps in Alcohol Treatment: Clinician Insights
NewsJan 23, 2026

Integrating Smartphone Apps in Alcohol Treatment: Clinician Insights

A recent study by Östh, Lundin and Wennberg surveyed clinicians on using smartphone app data in alcohol‑dependency treatment. The research found that practitioners value real‑time patient data for tailoring interventions and enhancing engagement, but cite technical glitches, privacy worries, and...

By Bioengineer.org
Novel Mouse Model for Gnaq p.R183Q Capillary Malformation
NewsJan 23, 2026

Novel Mouse Model for Gnaq p.R183Q Capillary Malformation

Researchers have introduced a genetically engineered mouse model carrying the Gnaq p.R183Q mutation, which replicates human capillary malformations. The model exhibits localized vascular ectasia, increased endothelial proliferation, and recapitulates the dermal phenotype seen in patients. Functional assays reveal hyperactive Gαq...

By Bioengineer.org
Stigmasterol Boosts Testicular and Sperm Function in Mice
NewsJan 23, 2026

Stigmasterol Boosts Testicular and Sperm Function in Mice

Researchers at a leading biomedical institute reported that dietary stigmasterol markedly improves testicular health and sperm parameters in male mice. The study administered a 50 mg/kg oral dose for eight weeks, resulting in a 30% rise in sperm count and enhanced...

By Bioengineer.org
Unraveling Small-Cell Lung Cancer: A Multi-Omic Approach
NewsJan 23, 2026

Unraveling Small-Cell Lung Cancer: A Multi-Omic Approach

Researchers performed an extensive multi‑omic analysis of small‑cell lung cancer, integrating genomics, transcriptomics, proteomics and metabolomics. The study identified several molecular subtypes with unique genetic mutations, expression signatures and metabolic profiles, and uncovered an immunosuppressive tumor microenvironment. Proteomic screening revealed...

By Bioengineer.org
III-Nitrides Enable Mini UV Spectral Imager
NewsJan 23, 2026

III-Nitrides Enable Mini UV Spectral Imager

Researchers Zhao, Li, and Ooi have demonstrated a miniaturized ultraviolet spectral imager built on III‑nitride semiconductor technology. By integrating a dense array of GaN‑based photodetectors with on‑chip waveguides and nanoscale gratings, the device achieves benchtop‑level spectral resolution in a handheld...

By Bioengineer.org
Mapping Neurodevelopment in Preterm Infants Using Machine Learning
NewsJan 23, 2026

Mapping Neurodevelopment in Preterm Infants Using Machine Learning

A multidisciplinary team applied deep‑learning algorithms to longitudinal MRI and EEG datasets from preterm infants, creating a predictive model of brain maturation. The model achieved over 85% accuracy in forecasting neurodevelopmental outcomes such as cognitive delay and cerebral palsy. By...

By Bioengineer.org
Neural Crest Cells Regulate Heart Development via Wnt
NewsJan 23, 2026

Neural Crest Cells Regulate Heart Development via Wnt

Researchers have uncovered that neural crest cells (NCCs) orchestrate heart formation by modulating the Wnt signaling cascade. Using genetically engineered mouse models, the team demonstrated that NCC‑derived Wnt ligands are essential for proper outflow‑tract alignment and septation. Disruption of Wnt...

By Bioengineer.org
Drones and Satellites Can Measure Methane Emissions From Ruminants
NewsJan 23, 2026

Drones and Satellites Can Measure Methane Emissions From Ruminants

A multinational research team has demonstrated that drones equipped with methane sensors, combined with flux‑tower wind data and hyperspectral satellite imagery, can accurately quantify methane emissions from African livestock, including cattle, goats, sheep, and camels. Test flights in Norway and...

By Phys.org – Biotechnology
Endostatin’s Nuclear Transport Driven by Nucleolin in Endothelial Cells
NewsJan 23, 2026

Endostatin’s Nuclear Transport Driven by Nucleolin in Endothelial Cells

Researchers have identified nucleolin as the primary carrier that shuttles endostatin into the nucleus of endothelial cells. The study demonstrates a direct binding interaction, enabling endostatin to modulate gene expression linked to angiogenesis. Nuclear localization of endostatin markedly reduces VEGF‑driven...

By Bioengineer.org
High‑MYC Tumors Evade the Immune System by Clearing R‑Loop Alarm Signals
NewsJan 23, 2026

High‑MYC Tumors Evade the Immune System by Clearing R‑Loop Alarm Signals

Researchers published in Cell reveal that high‑MYC tumors evade immune detection by binding nascent RNA and clearing R‑loop structures that would otherwise trigger innate immune signaling. MYC multimerizes, forms condensates with the nuclear exosome, and uses its RBRIII RNA‑binding domain...

By GEN (Genetic Engineering & Biotechnology News)
Plasma Proteomic Profiles of Elite HIV Controllers
NewsJan 23, 2026

Plasma Proteomic Profiles of Elite HIV Controllers

Researchers analyzed plasma proteomes of elite HIV controllers, a rare group that naturally suppresses viral replication without therapy. Using high‑resolution mass spectrometry, they identified a distinct protein signature marked by lower inflammatory mediators and altered metabolic pathways. Comparative analysis with...

By Bioengineer.org
Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop
NewsJan 23, 2026

Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop

Corcept Therapeutics reported positive Phase III results for relacorilant in platinum‑resistant ovarian cancer, meeting the overall survival endpoint. The data lifted the stock after a steep decline following a complete response letter that had cut the company's market value by half...

By BioCentury
Corxel Draws $287M Round to Drive Global Development of Oral GLP-1
NewsJan 23, 2026

Corxel Draws $287M Round to Drive Global Development of Oral GLP-1

Corxel Pharmaceuticals announced a $287 million Series D‑1 financing round aimed at advancing its oral GLP‑1 therapy into late‑stage clinical trials. The capital will enable the company to move beyond its China‑only data and pursue a global development strategy. Existing backers RTW...

By BioCentury
Association Between Maternal Infections During Pregnancy and Offspring Suicide Risk: A National Cohort Study
NewsJan 23, 2026

Association Between Maternal Infections During Pregnancy and Offspring Suicide Risk: A National Cohort Study

A nationwide Danish cohort study examined whether maternal infections during pregnancy raise the risk of suicide in offspring. Using linked health registers, the researchers identified over 1.2 million births and tracked maternal infection diagnoses alongside suicide outcomes up to age...

By Nature (Biotechnology)
Astellas’ Okamura: The Bottleneck Isn’t Money — It’s Translation
NewsJan 22, 2026

Astellas’ Okamura: The Bottleneck Isn’t Money — It’s Translation

Astellas CEO Naoki Okamura argues that Japan’s biotech sector is constrained more by the ability to translate scientific discoveries into market‑ready products than by a lack of capital. He outlines Astellas’ strategic focus on cell and gene therapies, a menopause...

By BioCentury
The Wild Card in the G12D Space
BlogJan 22, 2026

The Wild Card in the G12D Space

The KRAS G12D inhibitor market is heating up as Jiangsu Hengrui, Revolution Medicines and Genfleet announce early‑stage programs, joining Astellas, which first entered the clinic with a KRAS G12D degrader. A new Chinese biotech has released preliminary clinical data, claiming...

By Biotech Strategy Blog
Glucocorticoid Receptor Levels Link to Zebrafish Lateralization
NewsJan 22, 2026

Glucocorticoid Receptor Levels Link to Zebrafish Lateralization

Researchers have discovered that glucocorticoid receptor (GR) expression directly influences cerebral lateralization in zebrafish embryos. Using CRISPR‑mediated knock‑down and over‑expression assays, the team quantified asymmetrical gene‑expression patterns and behavioral turning bias. Zebrafish with elevated GR levels showed pronounced left‑right brain...

By Bioengineer.org
Doctors’ Views on AI Chatbots in Clinical Decisions
NewsJan 22, 2026

Doctors’ Views on AI Chatbots in Clinical Decisions

A recent survey of 1,200 physicians across the United States reveals that 68% view AI chatbots as useful adjuncts in clinical decision‑making, while 22% remain skeptical about their reliability. Doctors cite faster information retrieval and patient education as primary benefits,...

By Bioengineer.org
PRDM16 Expression: Key Prognostic Factor in AML
NewsJan 22, 2026

PRDM16 Expression: Key Prognostic Factor in AML

A new multi‑institutional study identifies high PRDM16 expression as a powerful prognostic marker in acute myeloid leukemia (AML). Analysis of over 500 patient transcriptomes shows that elevated PRDM16 correlates with significantly shorter overall survival and remains independent of established risk...

By Bioengineer.org
USP Develops Digital Quality Standards for Global Pharmaceutical Manufacturing
NewsJan 22, 2026

USP Develops Digital Quality Standards for Global Pharmaceutical Manufacturing

The United States Pharmacopeia (USP) is creating digital reference standards (dRS) and digitally structured compendial methods (dDS) to support digital‑first pharmaceutical workflows. These standards will be incorporated into the USP‑NF, allowing manufacturers to use machine‑readable data instead of physical materials....

By Pharmaceutical Technology
Oligodendrocyte Differentiation Holds Promise for MS Treatment Development
NewsJan 22, 2026

Oligodendrocyte Differentiation Holds Promise for MS Treatment Development

Johns Hopkins researchers led by Dwight Bergles uncovered that oligodendrocyte precursor cells (OPCs) continuously differentiate into myelinating oligodendrocytes, a process they term constitutive differentiation. Using cross‑species gene‑expression profiling, protein localization, and live‑mouse time‑lapse microscopy, they identified distinctive “dandelion clock‑like” extracellular...

By GEN (Genetic Engineering & Biotechnology News)
Predicting Post-Induction Hypotension in Elderly with Echocardiography
NewsJan 22, 2026

Predicting Post-Induction Hypotension in Elderly with Echocardiography

A recent study demonstrates that pre‑operative transthoracic echocardiography can reliably predict post‑induction hypotension (PIH) in patients over 65. Specific echo metrics, especially markers of diastolic dysfunction, showed strong correlation with intra‑operative blood pressure drops. The predictive model achieved over 80%...

By Bioengineer.org
Stingrays Inspire Smarter Ocean Robots: The Physics of Fin Motion
NewsJan 22, 2026

Stingrays Inspire Smarter Ocean Robots: The Physics of Fin Motion

Researchers at the University of California, Riverside have built robotic fins that replicate stingray swimming mechanics, revealing how the animals achieve precise maneuverability. High‑speed video and fluid‑dynamic modeling showed that subtle fin curvature and timing generate lift and thrust efficiently....

By Phys.org – Biotechnology
Early Diagnosis Key to Managing Developmental Disorders
NewsJan 22, 2026

Early Diagnosis Key to Managing Developmental Disorders

Early diagnosis is emerging as the linchpin for effective management of developmental disorders, with recent studies showing that interventions before age three dramatically improve functional outcomes. A multinational cohort of 12,000 infants revealed a 25% boost in adaptive behavior scores...

By Bioengineer.org
Single Enzyme Streamlines Production of All Four RNA Building Blocks
NewsJan 22, 2026

Single Enzyme Streamlines Production of All Four RNA Building Blocks

Researchers at the Institute of Science Tokyo have identified a novel enzyme, MAN PPK2, that universally phosphorylates all four RNA nucleotides into nucleoside triphosphates. The enzyme uses inexpensive polyphosphate as a phosphate donor, enabling a single‑step, low‑cost conversion of monophosphate and...

By Phys.org – Biotechnology
High Court Picked Hikma’s ‘Skinny Label’ Fight After Letting the Issue ‘Percolate’
NewsJan 22, 2026

High Court Picked Hikma’s ‘Skinny Label’ Fight After Letting the Issue ‘Percolate’

The U.S. Supreme Court has agreed to hear Hikma Pharmaceuticals’ challenge over the use of “skinny labels,” a practice that allows generic manufacturers to market lower‑cost versions of drugs without copying the original brand’s full label. The case follows years...

By Endpoints News
Pharma Bets Big on AI Platforms with Flurry of New Year Deals
NewsJan 22, 2026

Pharma Bets Big on AI Platforms with Flurry of New Year Deals

In early 2026 pharma giants Eli Lilly, GSK and Pfizer announced multi‑year AI platform agreements with start‑ups Chai Discovery, Noetik, and Boltz. Chai’s de novo antibody design model, Chai‑2, claims double‑digit success rates—over 100‑fold better than prior methods—while Noetik secured a $50 million...

By GEN (Genetic Engineering & Biotechnology News)
Drugmakers Spent Less on Washington Lobbying in 2025's Final Quarter
NewsJan 22, 2026

Drugmakers Spent Less on Washington Lobbying in 2025's Final Quarter

The five largest biotech firms reduced their congressional lobbying expenditures in the fourth quarter of 2025, marking a modest decline from the previous quarter. Collectively, they spent roughly $45 million, down about 4 percent year‑over‑year. The dip reflects tighter corporate budgets and...

By Endpoints News
Resurrected Ancient Enzyme Offers New Window Into Early Earth and the Search for Life Beyond It
NewsJan 22, 2026

Resurrected Ancient Enzyme Offers New Window Into Early Earth and the Search for Life Beyond It

University of Wisconsin–Madison researchers have resurrected a 3.2‑billion‑year‑old nitrogenase enzyme and expressed it in modern microbes. Their experiments show the ancient enzyme produces isotopic signatures identical to those of contemporary nitrogenase, confirming the reliability of these signatures as biosignatures in...

By Phys.org - Space News
ACIP Chair Calls for Reassessing Polio Vaccine Necessity
SocialJan 22, 2026

ACIP Chair Calls for Reassessing Polio Vaccine Necessity

So we are the point of questioning polio vaccines. The chair of ACIP: “I think also, as you look at polio, we need to not be afraid to consider that we are in a different time now than we were then....

By Matthew Herper
New ACIP Chair Questions Polio Vaccines, Rejects Established Science
SocialJan 22, 2026

New ACIP Chair Questions Polio Vaccines, Rejects Established Science

The new chair of the #ACIP was on the Why Should I Trust You? podcast. The interview was ... enlightening. Among other things, Kirk Milhoan seemed to question whether kids still need to be vaccinated against polio & said he...

By Helen Branswell
2025 Novel Small Molecule FDA Drug Approvals
BlogJan 22, 2026

2025 Novel Small Molecule FDA Drug Approvals

In 2025 the FDA approved 31 novel small‑molecule drugs, representing 67% of all new drug launches and a slight decline from the previous year. Oncology dominated the portfolio with nine approvals, while 29% were first‑in‑class therapies and 22% received accelerated...

By Drug Hunter
FDA Lays Out New Path to Speed Development of Multiple Myeloma Drugs
NewsJan 22, 2026

FDA Lays Out New Path to Speed Development of Multiple Myeloma Drugs

The FDA released new guidance allowing accelerated approval of multiple myeloma therapies based on minimal residual disease (MRD) or complete response endpoints. This shift lets sponsors use single‑arm or randomized trials focused on deep molecular responses, reducing the need for...

By BioPharma Dive
Corcept's Drug Extends Patients' Lives in Key Ovarian Cancer Study
NewsJan 22, 2026

Corcept's Drug Extends Patients' Lives in Key Ovarian Cancer Study

Corcept Therapeutics announced that its experimental drug, when combined with standard chemotherapy, cut the risk of death by 35% for patients with a difficult-to‑treat form of ovarian cancer. The reduction was observed in a Phase 2 trial that met its primary...

By Endpoints News
U.S. Exit From WHO Undermines Global Pandemic Preparedness
SocialJan 22, 2026

U.S. Exit From WHO Undermines Global Pandemic Preparedness

The US withdrawal from #WHO became official today, leaving the world less prepared for dangerous disease outbreaks. “When that will bite us in the ass, it’s impossible to predict. But there is a 100% certainty that it will bite us...

By Helen Branswell
Roche Boosts NC Factory Investment to $2B; Rentschler CEO Steps Down
NewsJan 22, 2026

Roche Boosts NC Factory Investment to $2B; Rentschler CEO Steps Down

Roche’s Genentech is increasing its capital outlay for the Holly Springs, North Carolina manufacturing complex to nearly $2 billion, marking a substantial boost to its U.S. production capacity. The additional funds will expand biologics and vaccine output, positioning the site as a...

By Endpoints News
Bristol Myers Signs Deal with Janux on T Cell Engager for $50M Upfront
NewsJan 22, 2026

Bristol Myers Signs Deal with Janux on T Cell Engager for $50M Upfront

Bristol Myers Squibb has entered a collaboration with San‑diego biotech Janux Therapeutics to develop a novel tumor‑activated T‑cell engager for solid cancers. The agreement provides Janux with a $50 million upfront cash payment, along with potential milestone and royalty payments. Janux...

By Endpoints News
DNA Nanodevices Reveal Acidic Nanolayer on Lysosome Surfaces in Live Cells
NewsJan 22, 2026

DNA Nanodevices Reveal Acidic Nanolayer on Lysosome Surfaces in Live Cells

The research team introduced ratiometric DNA nanodevices anchored to the cytosolic leaflet of lysosomes, enabling direct measurement of juxta‑lysosomal pH in living cells. They discovered a previously unknown acidic nanolayer up to 21 nm thick on the outer lysosomal membrane, whose...

By Phys.org – Nanotechnology